Puma Biotechnology Company Top Insiders

PBYI Stock  USD 3.39  0.16  4.95%   
Puma Biotechnology's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Puma Biotechnology suggests that almost all insiders are panicking. Puma Biotechnology employs about 185 people. The company is managed by 7 executives with a total tenure of roughly 27 years, averaging almost 3.0 years of service per executive, having 26.43 employees per reported executive.
Alan Auerbach  Chairman
Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee

Puma Biotechnology's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-08-12Michael Patrick MillerDisposed 23358 @ 3.49View
2024-07-17Maximo F NouguesDisposed 4156 @ 3.7View
2024-07-02Maximo F NouguesDisposed 5295 @ 3.27View
2024-06-13Troy Edward WilsonDisposed 27000 @ 3.33View
2024-01-03Maximo F NouguesDisposed 15682 @ 4.49View
Monitoring Puma Biotechnology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Puma Biotechnology's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Puma Biotechnology's future performance. Based on our forecasts, it is anticipated that Puma will maintain a workforce of under 190 employees by January 2025.
 
Yuan Drop
 
Covid

Puma Biotechnology Management Team Effectiveness

The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4232 %, meaning that it created $0.4232 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The Puma Biotechnology's current Return On Tangible Assets is estimated to increase to 0.13. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.26. As of now, Puma Biotechnology's Return On Assets are increasing as compared to previous years.
The Puma Biotechnology's current Net Income Applicable To Common Shares is estimated to increase to 2,415, while Common Stock Shares Outstanding is projected to decrease to under 32.7 M.

Puma Biotechnology Workforce Comparison

Puma Biotechnology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 7,472. Puma Biotechnology holds roughly 185 in number of employees claiming about 2.48% of equities under Health Care industry.

Puma Biotechnology Profit Margins

The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.27 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.27.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.880.734
Fairly Up
Very volatile

Puma Biotechnology Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Puma Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Puma Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Puma Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
1.4
7
5
 189,000 
 96,900 
2024-03-01
2.4
12
5
 760,378 
 86,125 
2023-06-01
1.0
7
7
 189,000 
 109,669 
2023-03-01
2.0
10
5
 1,000,327 
 51,993 
2022-12-01
0.1
1
10
 568,181 
 6,047 
2022-09-01
0.1538
2
13
 200,000 
 82,499 
2022-06-01
0.4286
6
14
 162,000 
 97,623 
2022-03-01
1.0909
12
11
 2,688,409 
 68,403 
2021-09-01
0.1111
1
9
 108,721 
 11,182 
2021-06-01
0.2917
7
24
 257,148 
 164,641 
2021-03-01
1.0833
13
12
 839,864 
 37,855 
2020-09-01
0.125
1
8
 93,953 
 14,395 
2020-06-01
0.7
7
10
 180,236 
 46,262 
2020-03-01
1.0
10
10
 841,061 
 11,569 
2019-12-01
0.2857
2
7
 210,507 
 1,699 
2019-09-01
0.0909
1
11
 4,500 
 19,933 
2019-06-01
0.8333
5
6
 97,115 
 1,712 
2019-03-01
0.5833
7
12
 188,749 
 21,560 
2018-12-01
1.0
1
1
 90,000 
 1,239 
2018-06-01
5.0
5
1
 28,770 
 1,211 
2018-03-01
2.0
10
5
 279,885 
 24,079 
2017-09-01
0.2857
4
14
 35,000 
 87,825 
2017-06-01
0.1667
5
30
 51,416 
 1,990,088 
2017-03-01
0.625
5
8
 180,250 
 23,145 
2016-09-01
1.0
1
1
 90,000 
 0.00 
2015-09-01
4.5
9
2
 294,500 
 6,000 
2013-12-01
12.0
12
1
 727,149 
 0.00 
2011-12-01
0.5
2
4
 166,551 
 3,000,000 

Puma Biotechnology Notable Stakeholders

A Puma Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Puma Biotechnology often face trade-offs trying to please all of them. Puma Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Puma Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alan AuerbachFounder, Chairman, CEO and President Secretary and Member of Stock Option CommitteeProfile
Maximo NouguesCFO OfficerProfile
Mariann OhanesianSenior Director, Investor RelationsProfile
Jeffrey LudwigChief OfficerProfile
Alvin PharmdChief OfficerProfile
FRAPS BScPharmacovigilance, AffairsProfile
Bo ChaoSenior DevelopmentProfile

About Puma Biotechnology Management Performance

The success or failure of an entity such as Puma Biotechnology often depends on how effective the management is. Puma Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Puma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Puma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.13  0.13 
Return On Capital Employed 0.25  0.26 
Return On Assets 0.09  0.10 
Return On Equity 0.40  0.42 

Puma Biotechnology Workforce Analysis

Traditionally, organizations such as Puma Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Puma Biotechnology within its industry.

Puma Biotechnology Manpower Efficiency

Return on Puma Biotechnology Manpower

Revenue Per Employee1.3M
Revenue Per Executive33.7M
Net Income Per Employee116.7K
Net Income Per Executive3.1M
Working Capital Per Employee307K
Working Capital Per Executive8.1M

Complementary Tools for Puma Stock analysis

When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements